For 23 GT-1/4 nave cirrhotic individuals treated with mericitabine 1000mg BID and PR for 24 or 48 weeks, the SVR rate was 38%versus22% in PR arms [Wedemeyeretal.2012;Pockrosetal.2012]. quadruple regimen with PR is able to cure almost all GT-1 null-responders. The development of pan-genotypic DAAs (NIs or NS5A.I) allows new mixtures with or without PR that increase the rate of sustained virological response (SVR) for those individuals, even for those with cirrhosis and independently of the genotype. Therefore, the near future of HCV treatment looks promising. The purpose of this article is definitely to provide an overview of the medical results recently reported for HCV treatment in GT-1 individuals. Keywords:Hepatitis C treatment, genotype 1, cirrhosis, decompensated cirrhosis, eRVR, SVR == Intro == Approximately 170200 million people worldwide (3% of the world’s populace) are chronically infected with the hepatitis C computer virus (HCV). HCV prevalence and genotype distribution vary around the world. Among the six identified HCV genotypes, genotype 1 (GT-1) is the most prevalent worldwide. It is the most difficult to cure with the standard-of-care treatment: the combination of pegylated interferon (PEG-IFN) alpha and ribavirin (RBV). Chronic hepatitis C can lead to cirrhosis and its subsequent complications such as hepatocellular carcinoma (HCC). Every year, more than 350,000 people die from hepatitis-C-related liver diseases. The goal of HCV treatment is usually to achieve a sustained virological response (SVR), which is usually defined as undetectable HCV RNA 6 months after cessation of therapy, leading to HCV mAChR-IN-1 clearance. SVR is usually associated with an improved histological outcome, and a reduction of morbidity and mortality. In 2011, the launch of the two first-generation protease inhibitors (PIs), boceprevir INPP4A antibody and telaprevir, was a major step forward for the treatment of GT-1-infected patients. Associated with PEG-IFN/RBV therapy (PR), these two drugs increase the chance of a cure for nave patients by 30% [Jacobsonet al.2011;Poordadet al.2011;Shermanet al.2011]. The benefit is usually even mAChR-IN-1 greater in treatment-experienced patients: the chance of a cure increases by 5060% for relapsers, 4045% for partial responders and 25% for null-responders [Baconet al.2011;Zeuzemet al.2011a]. However, only GT-1 patients benefit from this major advance [Wartelle-Bladouet al.2012]. Different potential therapeutic targets in the HCV lifecycle have been identified, which has led to the development of both direct antiviral brokers (DAAs) and brokers targeting the host functions that are essential for viral replication. In addition to the first-generation PIs, boceprevir and telaprevir, DAAs comprise second-wave and second-generation PIs, nucleoside/nucleotide inhibitors (NIs) and nonnucleoside inhibitors (NNIs) of the NS5B complex and NS5A inhibitors (NS5A.I). Host-targeting brokers (HTAs) are, e.g., cyclophilin inhibitors and silibinin. Next-generation DAAs appear to be promising; they may enable an interferon (IFN)-free regimen for cirrhotic patients and even for patients with more advanced or decompensated cirrhosis. The purpose of this article is usually to provide an overview of the recent clinical results concerning future HCV treatment of GT-1 patients. == Treatment of GT-1 patients with boceprevir or telaprevir beyond initial clinical trials == Triple therapy including boceprevir or mAChR-IN-1 telaprevir in mAChR-IN-1 combination with PR increases the SVR rates by 30% for nave patients and by even more for treatment-experienced patients. However, this benefit is usually associated with the increase of side effects such as anaemia and with the onset of new side effects: dysgeusia (nearly one-third of the patients treated with boceprevir) and cutaneous rash (55% of the patients treated with telaprevir) [Cacoubet al.2012]. Moreover, the triple regimen results in the increase of treatment withdrawals due to adverse events. Concerning anaemia management, these new treatments have led to a new paradigm: for noncirrhotic patients, the ribavirin dose can be reduced without impairing SVR, even at early stages of treatment when HCV RNA is still detectable [Sulkowskiet al.2012c;Poordadet al.2012d;Lawitzet.